1. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005; 366:378–384.
3. WHO. UNICEF. UNAIDS. Global Update on HIV Treatment 2013: Results, Impact and Opportunities. Geneva: WHO Press;2013.
4. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, Prasithsirikul W, Inthong Y, Chottanapund S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect. 2007; 55:464–469.
6. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013; 57:1038–1047.
7. Naicker DD, Wang B, Losina E, Zupkosky J, Bryan S, Reddy S, et al. Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, andbreadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection. Clin Infect Dis. 2012; 54:294–302.
8. Shrestha S, Wiener HW, Aissani B, Song W, Shendre A, Wilson CM, et al. Interleukin-10 (IL-10) pathway: genetic variants and outcomes of HIV-1 infection in African American adolescents. PLoS One. 2010; 5:e13384.
10. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, Butterworth AE, Pedersen BK, et al. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS. 2007; 21:2283–2291.
11. Wang C, Song W, Lobashevsky E, Wilson CM, Douglas SD, Mytilineos J, et al. Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 35:446–454.
13. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001; 19:683–765.
14. Ho AS. Interleukin-10 and its receptor. Ther Immunol. 1994; 1:173–185.
15. Korean Society for AIDS. The 2013 clinical guidelines for the diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. Infect Chemother. 2013; 45:455–461.
16. Kingkeow D, McNicholl JM, Maneekarn N, Wongtrakul J, Taechareonkul S, Suriyanon V, et al. Frequencies of IL10 SNP genotypes by multiplex PCR-SSP and their association with viral load and CD4 counts in HIV-1-infected Thais. Asian Pac J Allergy Immunol. 2011; 29:94–101.
17. Smolnikova MV. Association of IL2, TNFA, IL4 and IL10 promoter gene polymorphisms with the rate of progression of the HIV infection. Russ J Immunol. 2002; 7:349–356.
18. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002; 296:2225–2229.
19. International HapMap Consortium. The International HapMap Project. Nature. 2003; 426:789–796.
20. Jurinke C, van den Boom D, Cantor CR, Köster H. Automated genotyping using the DNA MassArray technology. Methods Mol Biol. 2002; 187:179–192.
21. Phillips MS, Lawrence R, Sachidanandam R, Morris AP, Balding DJ, Donaldson MA, et al. Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots. Nat Genet. 2003; 33:382–387.
22. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21:263–265.
24. Vasilescu A, Heath SC, Ivanova R, Hendel H, Do H, Mazoyer A, et al. Genomic analysis of Th1-Th2 cytokine genes in an AIDS cohort: identification of IL4 and IL10 haplotypes associated with the disease progression. Genes Immun. 2003; 4:441–449.
25. Wohl AR, Lu S, Turner J, Kovacs A, Witt M, Squires K, et al. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS. 2003; 17:267–275.
26. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Gevena: WHO press;2013.